SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Fermi, Inc. engages in the development of energy infrastructure. It intends to develop an energy and data center development campus to support the needs of to-be-built AI infrastructure. The company was founded by Rick Perry, Toby Neugebauer and Griffin Perry on January 10, 2025 and is headquartered in Amrillo, TX.

Fermi Inc

Fermi LLC

Fermi LLC is experiencing significant volatility as investors weigh speculative AI power infrastructure upside against ongoing concerns regarding a lack of signed tenants, pending leadership transitions, and upcoming shareholder lock-up expirations. Community sentiment remains deeply divided between those viewing recent pullbacks as an accumulation opportunity ahead of potential Project Matador developments and critics who are increasingly vocal about the company's lack of revenue and governance skepticism.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is experiencing a major surge and high trading volume following news that the Greenland government approved the company's acquisition of a controlling stake in the Tanbreez rare earth project. The community is buzzing with bullish sentiment, focusing on the stock's role as a strategic asset for Western supply chains, with many traders discussing the potential for a significant short squeeze.

Figma, Inc. is an AI-powered design platform that enables seamless collaboration across the entire product development lifecycle. Its products include FigJam, Figma Slides, Figma Design, Figma Draw, Dev Mode, Figma Sites, Figma Buzz and Figma Make. The company was founded by Dylan Joseph Field and Evan Darrow Wallace in 2012 and is headquartered in San Francisco, CA.

Figma Inc. - Ordinary Shares - Class A

Figma

Figma is experiencing extreme volatility driven by intense competition from new generative AI design tools and the broader market's aggressive repricing of high-growth SaaS stocks. While the community remains deeply divided between those viewing the stock as an oversold buying opportunity with strong fundamentals and others fearing it faces obsolescence from AI-integrated platforms, the stock continues to be heavily influenced by short-selling activity and ongoing institutional selling pressure.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Sellas Life Sciences is seeing significant community discussion and retail engagement as investors eagerly anticipate upcoming AACR presentations and trial data updates for their cancer therapy candidates. The stock is currently characterized by high volatility and heavy short interest, fueling active debates between bulls focused on potential buyout value and bears expressing skepticism over trial design and clinical data.

AEVEX Corp. operates as a holding company. It operates through Tactical Systems and Global Solutions segments. The Tactical Systems segment focuses on design, development, and production of autonomous systems including unmanned aerial systems and unmanned surface vessels. The Global Solutions segment offers services and mission support to defense and intelligence customers. The company was founded in 2017 and is headquartered in Solana Beach, CA.

AEVEX Corp. - Ordinary Shares - Class A

AEVEX Corp. is capturing significant market attention following its NYSE debut, with investors closely monitoring the drone and autonomous defense specialist as a new pure-play entry in a sector currently seeing high demand. The community is actively debating the stock's momentum potential and long-term viability, weighing the excitement of a fresh IPO against concerns regarding price volatility and potential profit-taking.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is trending as investors focus on upcoming clinical data presentations and the potential for a BLA submission, with community members actively discussing a technical breakout and the stock's significant institutional interest. Sentiment is polarized between long-term shareholders anticipating a potential acquisition or partnership based on the platform's prostate cancer data and vocal critics expressing frustration over extended timelines and dilution concerns.

"What's Updog?" is a Community Led token.

UpDog

UpDog is capturing community attention through persistent engagement, meme-focused social media campaigns, and efforts to integrate into various ecosystem poker and swap platforms. Investors are actively discussing the project's long-term presence in the Solana memecoin sector while engaging in community-led initiatives to boost visibility across social channels.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy is experiencing heightened momentum as investors react to a structural shift involving a move toward bi-monthly dividends, which the community sees as a catalyst for capital efficiency and reduced volatility. Traders are actively debating the stock's role as a leveraged proxy for Bitcoin, with bullish sentiment surging as participants monitor key technical breakouts and institutional accumulation patterns.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is facing significant volatility following a short-seller report from Wolfpack Research, which alleges stock promotion and raises concerns regarding the company's Passive Foreign Investment Company (PFIC) tax status. The community is actively debating the report's credibility, with many long-term investors dismissing the claims as a 'short and distort' tactic intended to shake out retail shares, while others are emphasizing management's quick response to redomicile the company in the U.S. as a strategic move to eliminate these tax complexities and strengthen their position in the AI infrastructure market.

PolySwarm

PolySwarm is capturing community attention as traders monitor technical indicators and speculate on a potential breakout driven by its cybersecurity utility in an AI-focused market. Investors are actively discussing whale accumulation and the impact of low circulating supply while awaiting a major catalyst to trigger a sustained price shift.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Enliven Therapeutics (NASDAQ:ELVN) Hits New 1-Year High - Time to Buy?

Enliven Therapeutics (NASDAQ:ELVN) Reaches New 12-Month High - Should You Buy...

Enliven Therapeutics, Inc. (NASDAQ:ELVN) Short Interest Down 26.3% in March

Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) was the recipient of a large drop in short interest in the month of March. As of March 31st, there was short interest totaling 6,053,456...

Enliven Therapeutics (NASDAQ:ELVN) Stock Price Down 4.2% - What's Next?

Enliven Therapeutics (NASDAQ:ELVN) Trading Down 4.2% - What's Next...

Enliven Therapeutics, Inc. (NASDAQ:ELVN) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) have earned a consensus rating of "Moderate Buy" from the six brokerages that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating and five have given a buy rating to...

Enliven Therapeutics (NASDAQ:ELVN) Sets New 12-Month High - Should You Buy?

Enliven Therapeutics (NASDAQ:ELVN) Hits New 52-Week High - Here's What Happened...

Q1 EPS Estimate for Enliven Therapeutics Reduced by Analyst

Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) - HC Wainwright dropped their Q1 2026 earnings per share (EPS) estimates for Enliven Therapeutics in a note issued to investors on Thursday...

Enliven Therapeutics (NASDAQ:ELVN) Given New $56.00 Price Target at HC Wainwright

HC Wainwright upped their price target on Enliven Therapeutics from $48.00 to $56.00 and gave the stock a "buy" rating in a research report on Thursday...

Enliven Therapeutics (NASDAQ:ELVN) Hits New 12-Month High on Analyst Upgrade

Enliven Therapeutics (NASDAQ:ELVN) Sets New 12-Month High Following Analyst Upgrade...

<ul class="summary-bullets"><li>Enliven's ELVN-001 is a high-potential investigational therapy with a best-in-class profile, offering a complementary mechanism to the approaches of Novartis’s Asciminib and TERN-701, the analyst said.&nbsp;</li><li>Clear sees ELVN-001 as a lower-risk, high-upside asset.</li><li>The late-stage ENABLE-2 trial of ELVN-001 in second line and beyond CML remains on track for the second half of 2026 initiation.</li></ul>Shares of Enliven Therapeutics Inc (ELVN) rallied 15% on Wednesday after Wall Street highlighted that Merck's (MRK) $6.7 billion acquisition of Terns Pharmaceuticals' (TERN) TERN-701 underscores the unmet need and opportunity for safer, more effective chronic myeloid leukemia (CML) therapies, similar to the kind Enliven is developing.Clear Street noted the opportunity for CML therapies despite generics. The acquisition signals growing interest in CML beyond Novartis (NVS), it added. Chronic myeloid leukemia (CML) is a slow-growing blood cancer where the bone marrow produces too many myeloid cells.In this context, Enliven's ELVN-001 is a high-potential investigational therapy with a best-in-class profile, offering a complementary mechanism to the approaches of Novartis’s Asciminib and TERN-701 and multiple strategic paths to value, the firm argued.Clear sees ELVN-001 as a lower-risk, high-upside asset. The late-stage ENABLE-2 trial of ELVN-001 in second line and beyond CML remains on track for the second half of 2026 initiation, pending U.S. Food and Drug Administration’s alignment on dose selection and trial design.<h2 class="st-heading-2">Merck-Terns Deal</h2>Merck said earlier on Wednesday that it has entered into a definitive agreement to acquire Terns for $53.00 per share in cash for an approximate equity value of $6.7 billion in a bid to add TERN-701 to its portfolio. TERN-701 is an experimental therapy currently in development for certain patients with CML. The transaction is expected to close in the second quarter of 2026, the company said, but analysts including RBC Capital and William Blair noted that it expects another bidder to emerge for Terns.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around ELVN stock rose from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume increased from ‘high’ to ‘extremely high’ levels.<a href="https://stocktwits.com/symbol/ELVN">ELVN stock</a> has gained 68% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/salesforce-reportedly-holding-back-on-raises-for-higher-level-employees/cZ3YDSyRISD">Salesforce Reportedly Holding Back On Raises For Higher-Level Employees</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Enliven Therapeutics, Inc. logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Terns Buyout Deal Ignites Optimism For Enliven Therapeutics’s Blood Cancer Portfolio

According to Clear Street, the Terns-Merck deal underscores the unmet need and opportunity for safer, more effective chronic myeloid leukemia (CML) therapies.

Equity

According to Clear Street, the Terns-Merck deal underscores the unmet need and opportunity for safer, more effective chronic myeloid leukemia (CML) therapies.


Enliven Therapeutics (NASDAQ:ELVN) Shares Gap Up After Analyst Upgrade

Enliven Therapeutics (NASDAQ:ELVN) Shares Gap Up Following Analyst Upgrade...

Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery and development of small molecule therapeutics. Its pipeline includes BCR-ABL Program: ELVN-001and HER2 Program: ELVN-002. The company was founded by Samuel S. Kintz, Joseph P. Lyssikatos, and Anish Patel on June 1, 2019 and is headquartered in Boulder, CO.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	-$0.44	--	--	N/A
Q4 '25	-$0.38	-$0.48	-24.68%	MISSED
Q3 '25	-$0.43	-$0.32	26.15%	BEAT
Q2 '25	-$0.54	-$0.49	8.72%	BEAT
Q1 '25	-$0.50	-$0.57	-13.66%	MISSED

ELVN
Enliven Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q1 '26

Historical Earnings

Latest ELVN News

ELVNEnliven Therapeutics Inc